Last Updated : May 13, 2025
Details
Generic Name:
acalabrutinib
Project Status:
Pending
Therapeutic Area:
Chronic lymphocytic leukemia (CLL).
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Calquence
Project Line:
Reimbursement Review
Project Number:
PC0412-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Acalabrutinib in combination with venetoclax for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Acalabrutinib in combination with venetoclax [with or without obinutuzumab] for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : May 13, 2025